Edesa Biotech P/E
Quel est le P/E de Edesa Biotech?
Le P/E de Edesa Biotech, Inc. est N/A
Quelle est la définition de P/E?
Le ratio cours / bénéfice est le rapport entre le prix des actions d'une entreprise et le bénéfice par action de l'entreprise calculé sur les douze derniers mois.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P/E des entreprises dans Health Care secteur sur NASDAQ par rapport à Edesa Biotech
Que fait Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Entreprises avec p/e similaire à Edesa Biotech
- Cannabix Technologies a P/E de N/A
- Antalis Ventures a P/E de N/A
- Fosterville South Exploration a P/E de N/A
- hmvod a P/E de N/A
- Commander Resources a P/E de N/A
- Rugby Mining a P/E de N/A
- Edesa Biotech a P/E de N/A
- Unitech a P/E de N/A
- Directa Plus Plc a P/E de N/A
- GURU Organic a P/E de N/A
- Amasse Capital a P/E de N/A
- Chen Xing Development a P/E de N/A
- Icade SA a P/E de N/A